<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: GSK&#8217;s Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer	</title>
	<atom:link href="https://9krapalm.com/gsks-jemperli-dostarlimab-plus-chemotherapy-approved-in-singapore-as-the-first-frontline-immuno-oncology-treatment-for-dmmr-msi-h-primary-advanced-or-recurrent-endometrial-cancer/feed/" rel="self" type="application/rss+xml" />
	<link>https://9krapalm.com/gsks-jemperli-dostarlimab-plus-chemotherapy-approved-in-singapore-as-the-first-frontline-immuno-oncology-treatment-for-dmmr-msi-h-primary-advanced-or-recurrent-endometrial-cancer/</link>
	<description>เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm</description>
	<lastBuildDate>Wed, 07 Aug 2024 01:49:37 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.4</generator>
</channel>
</rss>
